edoc-vmtest

Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues

Muros, M. A. and Varsavsky, M. and Iglesias Rozas, P. and Valdivia, J. and Delgado, J. R. and Forrer, F. and Bodei, L. and Paganelli, G.. (2009) Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clinical & translational oncology, Vol. 11 , Iss. 1. pp. 48-53.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6007063

Downloads: Statistics Overview

Abstract

To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: (90)Y-DOTATyr3- octreotide ((90)Y-DOTATOC) and (177)Lu-DOTA-Tyr3- octreotate ((177)Lu-DOTATATE).
Faculties and Departments:03 Faculty of Medicine > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
UniBasel Contributors:Forrer, Flavio
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Springer
ISSN:1699-048X
Note:Publication type according to Uni Basel Research Database: Journal article
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:45

Repository Staff Only: item control page